Skip to main content
OpenTrials
Completed

NCT Number: NCT07166484

Assessment of the Effect of the Product RV2666C Formula LA2984 Compared to an Untreated Area With an Epidermally Ablated Skin Model Obtained With an Erbium YAG Laser on Adults Presenting IV to VI Skin Phototype

In this study, we assess the efficacy of a cosmetic product in adults with IV to VI skin phototype.

This study is conducted as a monocentric, controlled, compared with an untreated area and randomized for the area of product application.

To perform this clinical study, minimum 20 - maximum 24 subjects (man or woman), aged from 18 to 50 years are enrolled.

The subjects applied the investigational product on an area located on the anterior side of the forearm, following the laser YAG act, once a day and under occlusion from Day 1 to Day 3 included. Then it is applied twice a day in an open way from Day 4 until Day 18 included.

10 visits are planned:

* Visit 1: Inclusion visit = Day 1 * Visit 2 to Visit 5: Intermediate visits = Day 2 to Day 5 * Visit 6: Intermediate visit = Day 8 * Visit 7: Intermediate visit = Day 10 * Visit 8: Intermediate visit = Day 12 * Visit 9: Intermediate visit = Day 15 * Visit 10: End of study visit = Day 19-1

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Skin Research Center

Toulouse, France, 31000

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Main inclusion criteria :

  • Man or woman from 18 to 50 years old
  • Phototype IV to VI according to the Fitzpatrick classification
  • Subject smoking ≤ 10 cigarettes/day containing nicotine, paper or e-cigarette equivalent
  • Subject agreeing not to expose his forearms to UV (natural or artificial) throughout the duration of the study and up to 3 months after the end of participation in the study
  • Subject protected by a tetanus vaccination according to the vaccination schedule established by the Public Health Agency

Main non-inclusion criteria:

  • Subject suffering from a disease liable to affect the wound healing process according to the opinion of the investigator
  • Subject with a known history of allergy or contact dermatitis induced in particular by the latex, the plaster, the local anesthetic, the local antiseptic or one of the components of the study product
  • Subject with a disease including skin disease in progress on the upper limbs that may interfere with the interpretation of the evaluation criteria according to the opinion of the investigator
  • Topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational product according to the investigator's assessment

Treatment and study plan

Cosmetic product RV2666C LA2984

Other

The product is applied, according to randomization, on an area located on the anterior side of the forearm, following the laser YAG act, once a day and under occlusion from Day 1 to Day 3 included. Then it is applied twice a day in an open way from Day 4 until Day 18 included.

Primary outcomes

  1. Time to complete wound healing

    Time frame: Day 1 - Visit 1, Day 2 - Visit 2, Day 3 - Visit 3, Day 4 - Visit 4, Day 5 - Visit 5, Day 8 - Visit 6, Day 10 - Visit 7, Day 12 - Visit 8, Day 15 - Visit 9 and Day 19 - Visit 10.

    The wound disappearance is assessed by the investigator by clinical exam of the skin and from standardized photographs taken with a C Cube Caméra©.

  2. The erythema of the skin

    Time frame: Day 1 - Visit 1 (before and after laser YAG act), Day 2 - Visit 2, Day 3 - Visit 3, Day 4 - Visit 4, Day 5 - Visit 5, Day 8 - Visit 6, Day 10 - Visit 7, Day 12 - Visit 8, Day 15 - Visit 9 and Day 19 - Visit 10.

    The erythema of the skin is assessed objectively using treatment software from standardized photographs using a C Cube Camera©.

  3. The pigmentation of the skin

    Time frame: Day 1 - Visit 1 (before and after laser YAG act), Day 2 - Visit 2, Day 3 - Visit 3, Day 4 - Visit 4, Day 5 - Visit 5, Day 8 - Visit 6, Day 10 - Visit 7, Day 12 - Visit 8, Day 15 - Visit 9 and Day 19 - Visit 10.

    The pigmentation of the skin is assessed objectively using treatment software from standardized photographs using a C Cube Camera©.

  4. The skin marks

    Time frame: Day 2 - Visit 2, Day 3 - Visit 3, Day 4 - Visit 4, Day 5 - Visit 5, Day 8 - Visit 6, Day 10 - Visit 7, Day 12 - Visit 8, Day 15 - Visit 9 and Day 19 - Visit 10.

    The skin marks are evaluated by the investigator at the end of the study using standardized photographs taken with a C Cube© Camera and using an NRS-type evaluation scale from 0 to 10.

  5. The wound healing quality

    Time frame: Day 8 - Visit 6, Day 10 - Visit 7, Day 12 - Visit 8, Day 15 - Visit 9 and Day 19 - Visit 10.

    The wound healing quality is evaluated by the investigator at the end of the study using standardized photographs taken with a C Cube© Camera and using an NRS-type evaluation scale from 0 to 10.

  6. The global efficacy of the product

    Time frame: Day 19 - Visit 10

    The global efficacy of the product is assessed by the subject with a 7-questions questionnaire.

  7. The transepidermal water loss

    Time frame: Day 1 - Visit 1 (before and after laser YAG act), Day 2 - Visit 2, Day 3 - Visit 3, Day 4 - Visit 4, Day 5 - Visit 5, Day 8 - Visit 6, Day 10 - Visit 7, Day 12 - Visit 8, Day 15 - Visit 9 and Day 19 - Visit 10.

    The transepidermal water loss is measured by a clinical research technician using a Vapometer©.

  8. Standardized photographs in an illustrative purpose

    Time frame: Day 1 - Visit 1 (before and after laser YAG act), Day 2 - Visit 2, Day 3 - Visit 3, Day 4 - Visit 4, Day 5 - Visit 5, Day 8 - Visit 6, Day 10 - Visit 7, Day 12 - Visit 8, Day 15 - Visit 9 and Day 19 - Visit 10.

    Photographs in 2D and 3D are taken using a C Cube Camera©.

Sponsors and collaborators

Lead sponsor

Pierre Fabre Dermo Cosmetique

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Sep 10, 2025
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.